Aptose Biosciences (APS) Stock Forecast & Price Target

Compare

146 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

APS Analyst Ratings

Hold

0 Buy

1 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Aptose

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

APS Stock 12 Month Forecast

Average Price Target

C$2.40

▲(9.21% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Aptose Biosciences in the last 3 months. The average price target is C$2.40 with a high forecast of C$2.40 and a low forecast of C$2.40. The average price target represents a 9.21% change from the last price of C$2.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","17":"C$17","4.25":"C$4.25","8.5":"C$8.5","12.75":"C$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.404364209228243,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$2.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.4026647744,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$2.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.404364209228243,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$2.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.26,2.271104939171403,2.2822098783428064,2.2933148175142097,2.304419756685613,2.3155246958570164,2.3266296350284197,2.337734574199823,2.3488395133712263,2.3599444525426296,2.371049391714033,2.3821543308854363,2.3932592700568396,{"y":2.404364209228243,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.26,2.2709742134153843,2.281948426830769,2.2929226402461538,2.3038968536615383,2.314871067076923,2.3258452804923073,2.3368194939076923,2.347793707323077,2.3587679207384613,2.369742134153846,2.380716347569231,2.3916905609846153,{"y":2.4026647744,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.26,2.271104939171403,2.2822098783428064,2.2933148175142097,2.304419756685613,2.3155246958570164,2.3266296350284197,2.337734574199823,2.3488395133712263,2.3599444525426296,2.371049391714033,2.3821543308854363,2.3932592700568396,{"y":2.404364209228243,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.2,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.2,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.2,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.649,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.31,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetC$2.40

Average Price TargetC$2.40

Lowest Price TargetC$2.40

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew Venezia

Alliance Global Partners

C$2.41

Hold

9.55%

Upside

Downgraded

11/24/25

Aptose Biosciences downgraded to Neutral from Buy at Alliance GlobalAptose Biosciences downgraded to Neutral from Buy at Alliance Global

Joseph Pantginis

H.C. Wainwright

C$2.73→C$8.19

Buy

272.31%

Upside

Reiterated

03/31/25

Aptose Biosciences (APTO) PT Raised to $6 at H.C. WainwrightH.C. Wainwright analyst Joseph Pantginis raised the price target on Aptose Biosciences (NASDAQ: APTO) to $6.00 (from $2.00) while maintaining a Buy rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew Venezia

Alliance Global Partners

C$2.41

Hold

9.55%

Upside

Downgraded

11/24/25

Aptose Biosciences downgraded to Neutral from Buy at Alliance GlobalAptose Biosciences downgraded to Neutral from Buy at Alliance Global

Joseph Pantginis

H.C. Wainwright

C$2.73→C$8.19

Buy

272.31%

Upside

Reiterated

03/31/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aptose Biosciences

3 Months

xxx

Success Rate

0/5 ratings generated profit

Average Return

-58.92%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -58.92% per trade.

1 Year

Joseph PantginisH.C. Wainwright

Success Rate

0/5 ratings generated profit

Average Return

-69.86%

reiterated a buy rating 11 months ago

Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -69.86% per trade.

2 Years

xxx

Success Rate

0/5 ratings generated profit

Average Return

-69.42%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -69.42% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

APS Analyst Recommendation Trends

Rating

Apr 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, APS has received 0 Buy Ratings, 18 Hold Ratings, and 1 Sell Ratings. APS average Analyst price target in the past 3 months is 2.40.

Each month's total comprises the sum of three months' worth of ratings.

APS Financial Forecast

APS Earnings Forecast

The previous quarter’s earnings for APS were -C$2.75.

No data currently available

APS Sales Forecast

The previous quarter’s earnings for APS were C$0.00.

APS Stock Forecast FAQ

What is TSE:APS’s average 12-month price target, according to analysts?

Based on analyst ratings, Aptose Biosciences’s 12-month average price target is 2.40.

What is TSE:APS’s upside potential, based on the analysts’ average price target?

Aptose Biosciences has 9.21% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TSE:APS a Buy, Sell or Hold?

Aptose Biosciences has a consensus rating of Hold which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.

What is Aptose Biosciences’s price target?

The average price target for Aptose Biosciences is 2.40. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is C$2.40 ,the lowest forecast is C$2.40. The average price target represents 9.21% Increase from the current price of C$2.2.

What do analysts say about Aptose Biosciences?

Aptose Biosciences’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of TSE:APS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Aptose Biosciences (APS) Stock Forecast & Price Target

APS Analyst Ratings

APS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Aptose Biosciences

APS Analyst Recommendation Trends

APS Financial Forecast

APS Earnings Forecast

APS Sales Forecast

APS Stock Forecast FAQ

Detailed List of Analyst Forecasts